Reviva Pharmaceuticals (RVPH) Corporate presentation summary

Clinical development pipeline and market opportunity

• Brilaroxazine targets neuropsychiatric disorders including schizophrenia, bipolar disorder, major depressive disorder, and ADHD, with significant market opportunities projected for each indication by 2034-2035.

• RP1208, a triple reuptake inhibitor, is in development for inflammatory and metabolic diseases such as pulmonary arterial hypertension, idiopathic pulmonary fibrosis, psoriasis, depression, and obesity.

Schizophrenia landscape and unmet needs

• Schizophrenia affects 1.1% of the global population, with high rates of treatment resistance, discontinuation, and relapse.

• Key unmet needs include addressing neuroinflammation, negative symptoms, and improving adherence.

Brilaroxazine mechanism and clinical efficacy

• Brilaroxazine modulates serotonin and dopamine receptors, with additional effects on inflammatory cytokines and nicotinic receptors.

• Phase 3 RECOVER trial met its primary endpoint, showing a 10.1-point reduction in PANSS total score versus placebo (p<0.001), with early and sustained separation from placebo.

• Significant improvements were observed in negative symptoms, social cognition, and agitation, with effect sizes up to 0.8 in vocal biomarker-positive patients.

• Durable efficacy was maintained over one year, with up to a 19.4-point decrease in PANSS total score at the highest dose.